ReviewBiochimica et biophysica acta2012
Progress of molecular targeted therapies for prostate cancers.
Review in Biochimica et biophysica acta, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 50 citations in OpenAlex.
- Review
- Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells.Journal of natural medicines · 2023Article
- Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer.Marine drugs · 2020Article
- Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo.Molecules (Basel, Switzerland) · 2020Article
- Cyclohexanone curcumin analogs inhibit the progression of castration-resistant prostate cancer in vitro and in vivo.Cancer science · 2019Article
- Elevated Serum Sialic Acid Levels Predict Prostate Cancer As Well As Bone Metastases.Journal of Cancer · 2019Article
- MicroRNAs in prostate cancer: From function to biomarker discovery.Experimental biology and medicine (Maywood, N.J.) · 2018Review
- Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model.Journal of translational medicine · 2018Article
- Raman spectroscopy for accurately characterizing biomolecular changes in androgen-independent prostate cancer cells.Journal of biophotonics · 2018Article
- Drug Repositioning for Effective Prostate Cancer Treatment.Frontiers in physiology · 2018Review
- PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells.Cancer letters · 2017Article
- REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer.Scientific reports · 2017Article
- Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.Oncotarget · 2016Article
- Article
- Recent developments in receptor tyrosine kinases targeted anticancer therapy.Veterinary world · 2016Review
- Ovarian cancer transformation from adenocarcinoma to undifferentiated small cell carcinoma: A case report.Oncology letters · 2015Article
- Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues.Hormones & cancer · 2014Article
- Gonadotropin-releasing hormone agonists sensitize, and resensitize, prostate cancer cells to docetaxel in a p53-dependent manner.PloS one · 2014Article
- The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer.Cancer growth and metastasis · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Prostate cancer remains the most commonly diagnosed malignancy and the second leading cause of cancer-related deaths in men in the United States. The current standard of care consists of prostatectomy and radiation therapy, which may often be supplemented with hormonal therapies. Recurrence is common, and many develop metastatic prostate cancer for which chemotherapy is only moderately effective. It is clear that novel therapies are needed for the treatment of the malignant forms of prostate cancer that recur after initial therapies, such as hormone refractory (HRPC) or castration resistant prostate cancer (CRPC). With advances in understanding of the molecular mechanisms of cancer, we have witnessed unprecedented progress in developing new forms of targeted therapy. Several targeted therapeutic agents have been developed and clinically used for the treatment of solid tumors such as breast cancer, non-small cell lung cancer, and renal cancer. Some of these reagents modulate growth factors and/or their receptors, which are abundant in cancer cells. Other reagents target the downstream signal transduction, survival pathways, and angiogenesis pathways that are abnormally activated in transformed cells or metastatic tumors. We will review current developments in this field, focusing specifically on treatments that can be applied to prostate cancers. Finally we will describe aspects of the future direction of the field with respect to discovering biomarkers to aid in identifying responsive prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.